NCT02250222View on ClinicalTrials.gov

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

LGD-6972

LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

DRUG

Placebo (Captisol ®)

betadex \[β-cyclodextrin\] sulfobutylether sodium, NF

Trial Locations (3)

33014

Clinical Pharmacology of Miami, Inc, Miami

45227

Medpace Clinical Pharmacology, Cincinnati

85283

Celerion, Inc, Tempe

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY

NCT02250222 - Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter